Life Sciences

Postponement of ruling on key pharma “pipeline patents” case leaves Brazilian life sciences industry in lurch

Supreme Court has taken nearly a decade to rule on a constitutional challenge to a controversial law allowing pharma companies to bypass the regular patenting process

<strong>Postponement of ruling on key pharma “pipeline patents” case leaves Brazilian life sciences industry in lurch</strong>
17 Sep 2018

Patent controversy embroils South Korean biotech claiming key CRISPR IP

Questions emerge about whether ToolGen properly acquired foundational gene editing patents, and how much government support founder Kim Jin-soo received for his breakthrough invention.

14 Sep 2018

Broad Institute wins crucial CRISPR decision at CAFC, but patent battle with University of California is far from over

The Federal Circuit’s judgment in favour of Broad in a much-anticipated CRISPR case is unlikely to bring the hard-fought patent dispute with its West Coast rival to an end just yet.


View all
20 Sep 2018

The rise of biosimilars and the future of healthcare intellectual property

Litigation between rights holders of biologic drugs and producers of biosimilars is set to become an increasingly important part of the life sciences IP landscape Read more

13 Sep 2018

Chinese biotech patents fail to make mark, more litigation for AbbVie, AIDS Heath Foundation appeals to SCOTUS and much more

The August edition of our monthly round-up of the life sciences stories you need to know Read more

10 Sep 2018

It’s not done yet, but Trump trade deal could herald IP breakthrough for pharma innovators in Mexico

With a major focus on intellectual property, the new US-Mexico trade agreement may provide stronger data protection and patent rights Read more

4 Sep 2018

Predictions of 2018 pharma M&A surge fall flat, but patent licensing deals are at a record high

Despite forecasts of a sharp rise in pharma deal-making activity, it has proved to be a slow year on the M&A front. One reason may be that licensing partnerships are proving far more popular than many had expected. Read more


View all
9 Aug 2018

US pharma companies under increasing legislative pressure, key EU SPC decision and much more in July’s life sciences IP round-up

In this month’s round-up of patent news from the life sciences, we report on the latest blow to the St Regis Mohawks’ attempt shield their Restasis patents from inter partes review, the new bill seeking to roll out compulsory licensing in the US,… Read more

7 Jul 2018

All the big legal, market and deals news from the life sciences sector in June

In June’s round-up of life sciences-related news, we report on the US Supreme Court’s decision to grant certiorari in the Helsinn Healthcare v Teva Pharmaceuticals Section 102 dispute, but not in the Cleveland Clinic’s Section 101 case against True… Read more

26 Jun 2018

Car giants and China’s IP leaders among notable gainers in latest IPO US patent ranking

The Intellectual Property Owners Association (IPO) released its annual ranking yesterday of the 300 companies that received the most US patents in 2017. There was no change at number one as IBM held onto its customary position at the top of the pile… Read more

13 Jun 2018

The Battistelli legacy, China concerns, gambling opportunities and a whole lot more from IPBC Global 2018

The sessions on the third and final day of IPBC Global 2018 have now finished; and, like yesterday, the action has come thick and first across a variety of plenaries, breakouts and masterclasses. The members of IAM’s editorial team on the ground at… Read more


View all
24 Aug 2018

SCOTUS petition on HIV drug patents poses reputational as well as legal risks for pharma companies

An HIV/AIDS non-profit organisation is seeking a change in the law surrounding patent invalidity lawsuits. Read more

20 Aug 2018

Size of drug patent thickets highlighted by report, amidst intense pharma IP scrutiny

A new report revealing the large number of secondary patents granted, and applied for, by the owners of the US' best-selling drugs is sure to fuel the ongoing controversy over pharma IP rights. Read more

14 Aug 2018

CJEU’s failure to clear up SPC mess highlights difficulties with non-specialist judges

The disappointing recent Truvada SPC decision by Europe's highest court underscores the problems that arise when non-specialist judges rule on highly complex IP matters. Read more

7 Aug 2018

Why Chinese biotech inventions have yet to make an impact globally, despite patenting surge

A new academic article about patenting in the BRICS countries makes fascinating reading for life sciences IP professionals interested in gauging the development and current state of China’s biotechnology patent landscape. On the one hand, it… Read more